(1) This instrument is the National Health (Minimum Stockholding) Amendment Determination (No. 2) 2024.

(2) This instrument may also be cited as PB 24 of 2024.

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table	1 March 2024.	1 March 2024
2. Schedule 1	1 March 2024.	1 March 2024

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 99AEKC(2) of the National Health Act 1953.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 March 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1

After:

Amitriptyline

Tablet containing amitriptyline hydrochloride 50 mg

Oral

ENTRIP

(a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand

(b) after 31 December 2023—4.5 months stock by reference to usual demand

insert:

Amlodipine	Tablet 10 mg (as besilate)	Oral	Norvapine	between 1 March 2024 and 30 April 2024—0 months stock by reference to usual demand
Amlodipine	Tablet 5 mg (as besilate)	Oral	Norvapine	between 1 March 2024 and 30 April 2024—0 months stock by reference to usual demand

2 Schedule 1

Omit:

Atorvastatin

Tablet 20 mg (as calcium)

Oral

Atorvastatin GH

Between 1 October 2023 and 29 February 2024—0 months stock by reference to usual demand

3 Schedule 1

Omit:

Bisoprolol	Tablet containing bisoprolol fumarate 10 mg	Oral	Bisoprolol Dr.Reddy's	between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand
Bisoprolol	Tablet containing bisoprolol fumarate 2.5 mg	Oral	Bisoprolol Dr.Reddy's	between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand
Bisoprolol	Tablet containing bisoprolol fumarate 5 mg	Oral	Bisoprolol Dr.Reddy's	between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand

4 Schedule 1

Omit:

Clopidogrel

Tablet 75 mg (as besilate)

Oral

Clopidogrel GH

Between 1 October 2023 and 29 February 2024—0 months stock by reference to usual demand

5 Schedule 1

After:

Diclofenac

Tablet (enteric coated) containing diclofenac sodium 25 mg

Oral

Diclofenac Sandoz

between 1 November 2023 and 30 April 2024—4 months stock by reference to usual demand

insert:

Diclofenac

Tablet (enteric coated) containing diclofenac sodium 25 mg

Oral

Fenac 25

between 1 March 2024 and 31 March 2024—0 months stock by reference to usual demand

6 Schedule 1

Omit:

Diclofenac

Tablet (enteric coated) containing diclofenac sodium 50 mg

Oral

Fenac

(a) between 1 July 2023 and 31 December 2023—1 month stock by reference to usual demand

(b) after 31 December 2023—2 months stock by reference to usual demand

substitute:

Diclofenac

Tablet (enteric coated) containing diclofenac sodium 50 mg

Oral

Fenac

between 1 March 2024 and 31 March 2024—0 months stock by reference to usual demand

7 Schedule 1

Omit:

Ezetimibe with simvastatin

Tablet 10 mg‑10 mg

Oral

EZESIM 10/10

between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand

8 Schedule 1

Omit:

Ezetimibe with simvastatin

Tablet 10 mg‑20 mg

Oral

EZESIM 10/20

between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand

9 Schedule 1

Omit:

Ezetimibe with simvastatin

Tablet 10 mg‑40 mg

Oral

EZESIM 10/40

between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand

10 Schedule 1

Omit:

Ezetimibe with simvastatin

Tablet 10 mg‑80 mg

Oral

EZESIM 10/80

between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand

11 Schedule 1

Omit:

Filgrastim

Injection 300 micrograms in 1 mL

Injection

Neupogen

between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand

Filgrastim

Injection 480 micrograms in 1.6 mL

Injection

Neupogen

between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand

12 Schedule 1

After:

Folic acid

Tablet 500 micrograms

Oral

Megafol 0.5

4 months stock by reference to usual PBS demand

insert:

Folinic acid

Injection containing calcium folinate equivalent to 100 mg folinic acid in 10 mL

Injection

Leucovorin Calcium (Pfizer Australia Pty Ltd)

between 1 March 2024 and 31 July 2024—0 months stock by reference to usual demand

13 Schedule 1

Omit:

Glucose indicator‑urine

Test strips, 50 (Diastix)

For External Use

Diastix

between 1 December 2023 and 29 February 2024—0 months stock by reference to usual demand

14 Schedule 1

Omit:

Levetiracetam	Tablet 1 g	Oral	Levecetam 1000	between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand
Levetiracetam	Tablet 250 mg	Oral	Levecetam 250	between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand
Levetiracetam	Tablet 500 mg	Oral	Levecetam 500	between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand

15 Schedule 1

Omit:

Mitozantrone

Injection 20 mg (as hydrochloride) in 10 mL

Injection

Onkotrone

between 1 December 2023 and 29 February 2024—0 months stock by reference to usual demand

16 Schedule 1

Omit:

Mycophenolic acid

Capsule containing mycophenolate mofetil 250 mg

Oral

CellCept

between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand

substitute:

Mycophenolic acid

Capsule containing mycophenolate mofetil 250 mg

Oral

CellCept

between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand

17 Schedule 1

Omit:

Mycophenolic acid

Tablet containing mycophenolate mofetil 500 mg

Oral

CellCept

between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand

substitute:

Mycophenolic acid

Tablet containing mycophenolate mofetil 500 mg

Oral

CellCept

between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand

18 Schedule 1

Omit:

Telmisartan	Tablet 40 mg	Oral	Telmisartan-DRLA	between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand
Telmisartan	Tablet 80 mg	Oral	Telmisartan-DRLA	between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand

19 Schedule 1

After:

Topiramate

Tablet 100 mg

Oral

APO-Topiramate

3 months stock by reference to usual demand

insert:

Topiramate

Tablet 100 mg

Oral

Topamax

between 1 March 2024 and 30 April 2024—0 months stock by reference to usual demand

20 Schedule 1

After:

Topiramate

Tablet 200 mg

Oral

APO-Topiramate

3 months stock by reference to usual demand

insert:

Topiramate

Tablet 200 mg

Oral

Topamax

between 1 March 2024 and 30 April 2024—0 months stock by reference to usual demand

21 Schedule 1

After:

Topiramate

Tablet 25 mg

Oral

APO-Topiramate

3 months stock by reference to usual demand

insert:

Topiramate

Tablet 25 mg

Oral

Topamax

between 1 March 2024 and 30 April 2024—0 months stock by reference to usual demand

22 Schedule 1

After:

Topiramate

Tablet 50 mg

Oral

APO-Topiramate

3 months stock by reference to usual demand

insert:

Topiramate

Tablet 50 mg

Oral

Topamax

between 1 March 2024 and 30 April 2024—0 months stock by reference to usual demand